JP7514224B2 - マイクロサテライト不安定性を評価するための方法およびシステム - Google Patents
マイクロサテライト不安定性を評価するための方法およびシステム Download PDFInfo
- Publication number
- JP7514224B2 JP7514224B2 JP2021514069A JP2021514069A JP7514224B2 JP 7514224 B2 JP7514224 B2 JP 7514224B2 JP 2021514069 A JP2021514069 A JP 2021514069A JP 2021514069 A JP2021514069 A JP 2021514069A JP 7514224 B2 JP7514224 B2 JP 7514224B2
- Authority
- JP
- Japan
- Prior art keywords
- microsatellite
- subject
- repeat elements
- instability
- msi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000032818 Microsatellite Instability Diseases 0.000 title claims description 349
- 238000000034 method Methods 0.000 title claims description 136
- 108091092878 Microsatellite Proteins 0.000 claims description 328
- 206010028980 Neoplasm Diseases 0.000 claims description 115
- 238000012163 sequencing technique Methods 0.000 claims description 90
- 239000008280 blood Substances 0.000 claims description 62
- 210000004369 blood Anatomy 0.000 claims description 62
- 238000011282 treatment Methods 0.000 claims description 55
- 201000011510 cancer Diseases 0.000 claims description 45
- 230000035945 sensitivity Effects 0.000 claims description 43
- 108020004414 DNA Proteins 0.000 claims description 30
- 230000003321 amplification Effects 0.000 claims description 26
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 26
- 238000009169 immunotherapy Methods 0.000 claims description 23
- 238000012070 whole genome sequencing analysis Methods 0.000 claims description 23
- 238000012545 processing Methods 0.000 claims description 18
- 238000002512 chemotherapy Methods 0.000 claims description 12
- 238000001959 radiotherapy Methods 0.000 claims description 10
- 108091081062 Repeated sequence (DNA) Proteins 0.000 claims description 7
- 239000000523 sample Substances 0.000 description 47
- 150000007523 nucleic acids Chemical class 0.000 description 28
- 102000053602 DNA Human genes 0.000 description 27
- 102000039446 nucleic acids Human genes 0.000 description 21
- 108020004707 nucleic acids Proteins 0.000 description 21
- 238000012217 deletion Methods 0.000 description 19
- 230000037430 deletion Effects 0.000 description 19
- 230000015654 memory Effects 0.000 description 19
- 238000003860 storage Methods 0.000 description 18
- 238000003780 insertion Methods 0.000 description 16
- 230000037431 insertion Effects 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 229960002621 pembrolizumab Drugs 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 238000004393 prognosis Methods 0.000 description 9
- 206010009944 Colon cancer Diseases 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 7
- 210000004602 germ cell Anatomy 0.000 description 7
- 230000033607 mismatch repair Effects 0.000 description 7
- 238000004891 communication Methods 0.000 description 6
- 238000007481 next generation sequencing Methods 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- 206010014733 Endometrial cancer Diseases 0.000 description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 description 5
- 206010073073 Hepatobiliary cancer Diseases 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 208000000453 Skin Neoplasms Diseases 0.000 description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 description 5
- 208000006593 Urologic Neoplasms Diseases 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 206010017758 gastric cancer Diseases 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 201000000849 skin cancer Diseases 0.000 description 5
- 201000011549 stomach cancer Diseases 0.000 description 5
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 241000208125 Nicotiana Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 238000013500 data storage Methods 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 108700003861 Dominant Genes Proteins 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 2
- 206010051922 Hereditary non-polyposis colorectal cancer syndrome Diseases 0.000 description 2
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 2
- 201000005027 Lynch syndrome Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 108091092259 cell-free RNA Proteins 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 239000005549 deoxyribonucleoside Substances 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000012165 high-throughput sequencing Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101100521334 Mus musculus Prom1 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000011528 liquid biopsy Methods 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037843 metastatic solid tumor Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- -1 nucleoside monophosphates Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000007841 sequencing by ligation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000010454 slate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229950010342 uridine triphosphate Drugs 0.000 description 1
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Bioethics (AREA)
- Evolutionary Computation (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Data Mining & Analysis (AREA)
- Artificial Intelligence (AREA)
- Software Systems (AREA)
- Databases & Information Systems (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Surgery (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731718P | 2018-09-14 | 2018-09-14 | |
| US62/731,718 | 2018-09-14 | ||
| PCT/US2019/051138 WO2020056347A1 (en) | 2018-09-14 | 2019-09-13 | Methods and systems for assessing microsatellite instability |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022500764A JP2022500764A (ja) | 2022-01-04 |
| JP2022500764A5 JP2022500764A5 (https=) | 2022-09-22 |
| JPWO2020056347A5 JPWO2020056347A5 (https=) | 2022-09-22 |
| JP7514224B2 true JP7514224B2 (ja) | 2024-07-10 |
Family
ID=69777893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514069A Active JP7514224B2 (ja) | 2018-09-14 | 2019-09-13 | マイクロサテライト不安定性を評価するための方法およびシステム |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210358569A1 (https=) |
| EP (1) | EP3850111A4 (https=) |
| JP (1) | JP7514224B2 (https=) |
| KR (1) | KR20210092196A (https=) |
| CN (1) | CN112955570B (https=) |
| AU (1) | AU2019339511A1 (https=) |
| BR (1) | BR112021004763A2 (https=) |
| CA (1) | CA3112562A1 (https=) |
| IL (1) | IL281417A (https=) |
| SG (1) | SG11202102528UA (https=) |
| WO (1) | WO2020056347A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7539367B2 (ja) | 2018-08-31 | 2024-08-23 | ガーダント ヘルス， インコーポレイテッド | 無細胞ｄｎａにおけるマイクロサテライト不安定性の検出 |
| KR102781271B1 (ko) * | 2021-08-10 | 2025-03-17 | (주)디엑솜 | 현미부수체 지역의 서열 길이의 최대값과 최소값의 차이를 이용한 현미부수체 불안정성 진단방법 |
| KR102688594B1 (ko) * | 2021-08-10 | 2024-07-24 | (주)디엑솜 | 현미부수체 지역의 서열 길이의 변화율을 이용한 현미부수체 불안정성 진단방법 |
| CN114464257B (zh) * | 2022-03-15 | 2025-02-25 | 郑州安图生物工程股份有限公司 | 一种基于二代测序的微卫星不稳定性检测方法及装置 |
| CN118942537B (zh) * | 2023-09-21 | 2026-01-23 | 杭州链康医学检验实验室有限公司 | 一种构建标记微卫星位点稳定性预测模型的方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140235456A1 (en) | 2012-12-17 | 2014-08-21 | Virginia Tech Intellectual Properties, Inc. | Methods and Compositions for Identifying Global Microsatellite Instability and for Characterizing Informative Microsatellite Loci |
| JP2015516144A (ja) | 2012-04-10 | 2015-06-08 | ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ | 癌におけるマイクロサテライト不安定性を検出しｄｎａ塩基除去修復経路の阻害による合成致死性を決定するための新規なマーカー |
| WO2018037231A1 (en) | 2016-08-24 | 2018-03-01 | The University Of Newcastle Upon Tyne | Methods of identifying microsatellite instability |
| WO2018137678A1 (zh) | 2017-01-25 | 2018-08-02 | 广州燃石医学检验所有限公司 | 一种基于二代测序的同时检测微卫星位点稳定性和基因组变化的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017008165A1 (en) * | 2015-07-14 | 2017-01-19 | British Columbia Cancer Agency Branch | Classification method and treatment for endometrial cancers |
| EP3405574A4 (en) * | 2016-01-22 | 2019-10-02 | Grail, Inc. | VARIANTS-BASED SICKNESS DIAGNOSTICS AND PURSUIT |
| CA3083787A1 (en) * | 2017-12-01 | 2019-06-06 | Personal Genome Diagnositics Inc. | Process for microsatellite instability detection |
-
2019
- 2019-09-13 JP JP2021514069A patent/JP7514224B2/ja active Active
- 2019-09-13 BR BR112021004763-8A patent/BR112021004763A2/pt not_active Application Discontinuation
- 2019-09-13 SG SG11202102528UA patent/SG11202102528UA/en unknown
- 2019-09-13 CA CA3112562A patent/CA3112562A1/en active Pending
- 2019-09-13 CN CN201980069237.6A patent/CN112955570B/zh active Active
- 2019-09-13 US US17/275,160 patent/US20210358569A1/en active Pending
- 2019-09-13 KR KR1020217010575A patent/KR20210092196A/ko not_active Withdrawn
- 2019-09-13 AU AU2019339511A patent/AU2019339511A1/en not_active Abandoned
- 2019-09-13 EP EP19860919.0A patent/EP3850111A4/en active Pending
- 2019-09-13 WO PCT/US2019/051138 patent/WO2020056347A1/en not_active Ceased
-
2021
- 2021-03-11 IL IL281417A patent/IL281417A/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015516144A (ja) | 2012-04-10 | 2015-06-08 | ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ | 癌におけるマイクロサテライト不安定性を検出しｄｎａ塩基除去修復経路の阻害による合成致死性を決定するための新規なマーカー |
| US20140235456A1 (en) | 2012-12-17 | 2014-08-21 | Virginia Tech Intellectual Properties, Inc. | Methods and Compositions for Identifying Global Microsatellite Instability and for Characterizing Informative Microsatellite Loci |
| WO2018037231A1 (en) | 2016-08-24 | 2018-03-01 | The University Of Newcastle Upon Tyne | Methods of identifying microsatellite instability |
| WO2018137678A1 (zh) | 2017-01-25 | 2018-08-02 | 广州燃石医学检验所有限公司 | 一种基于二代测序的同时检测微卫星位点稳定性和基因组变化的方法 |
Non-Patent Citations (3)
| Title |
|---|
| BARZI Afsaneh，外７名，"Assessment of microsatellite instability (MSI) in cell free DNA (cfDNA) of colorectal cancers (CRC) patients (pts)"，Journal of Clinical Oncology [online]，米国，American Society of Clinical Oncology，2018年02月26日，[2023年11月14日検索]，インターネット<URL:https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.672> |
| G Sozzi，外７名，"診断時および肺癌患者の追跡中の血漿中の循環腫瘍DNAの分析 - Bibgraph (ビブグラフ)｜PubMedを日本語で論文検索"，Cancer research [online]，日本，Bibgraph，2001年06月15日，[2023年11月13日検索]，インターネット<URL:https://bibgraph.hpcr.jp/abst/pubmed/11406535?click_by=p_ref> |
| HEGELE A. Robert，外４名，"Genome-wide scanning for type 2 diabetes susceptibility in Canadian Oji-Cree, using 190 microsatellite markers"，Jpn Soc Hum Genet and Springer-Verlag 1999 [online]，Jpn Soc Hum Genet and Springer-Verlag 1999，1998年07月17日，[2023年11月13日検索]，インターネット<URL:https://www.nature.com/articles/jhg19992> |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021004763A2 (pt) | 2021-08-03 |
| KR20210092196A (ko) | 2021-07-23 |
| CA3112562A1 (en) | 2020-03-19 |
| SG11202102528UA (en) | 2021-04-29 |
| CN112955570B (zh) | 2025-01-21 |
| WO2020056347A1 (en) | 2020-03-19 |
| EP3850111A4 (en) | 2022-06-29 |
| JP2022500764A (ja) | 2022-01-04 |
| CN112955570A (zh) | 2021-06-11 |
| IL281417A (en) | 2021-04-29 |
| US20210358569A1 (en) | 2021-11-18 |
| AU2019339511A1 (en) | 2021-05-13 |
| EP3850111A1 (en) | 2021-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7022188B2 (ja) | 無細胞核酸の多重解像度分析のための方法 | |
| CN115667554B (zh) | 通过核酸甲基化分析检测结直肠癌的方法和系统 | |
| JP7514224B2 (ja) | マイクロサテライト不安定性を評価するための方法およびシステム | |
| JP7421474B2 (ja) | 腫瘍遺伝子変異量の正規化 | |
| KR20220061271A (ko) | 희귀 돌연변이 및 카피수 변이를 검출하기 위한 시스템 및 방법 | |
| US12509732B2 (en) | Methods of detecting tumor progression via analysis of cell-free nucleic acids | |
| TW202010845A (zh) | 組織特異性甲基化標記 | |
| JP2024056939A (ja) | 生体試料のフィンガープリンティングのための方法 | |
| JP2023540257A (ja) | がんを分類するためのサンプルの検証 | |
| US20220389522A1 (en) | Methods of assessing and monitoring tumor load | |
| JP7763764B2 (ja) | 標的バリアントがクローンレベルで存在しないことの有意性モデリング | |
| EP4695417A1 (en) | Methods and systems for cell-free nucleic acid processing | |
| US12509733B1 (en) | Methods and systems for detecting a primary disease | |
| CN116134546A (zh) | 用于诊断检验的有效样本混合的方法和系统 | |
| HK40042779A (en) | Tissue-specific methylation marker |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220913 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220913 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230726 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231025 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231117 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240417 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240611 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240628 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7514224 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |